FAQs on Annovis Bio Inc.'s Appointment of Hui Liu as Director of Biostatistics

Who has Annovis Bio Inc. recently appointed?

Annovis Bio Inc. has appointed Hui Liu as the Director of Biostatistics.

What is Hui Liu’s background?

Hui Liu brings over 19 years of experience in clinical trial design, analysis, and regulatory submission support across multiple therapeutic areas.

Why is Hui Liu’s appointment significant for Annovis Bio?

Her expertise is expected to reinforce the scientific integrity of Annovis Bio’s data and enhance regulatory strategies for developing transformative therapies for neurodegenerative disorders.

What is Annovis Bio Inc. focused on?

Annovis Bio is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s by developing innovative therapies that target multiple neurotoxic proteins.

Where is Annovis Bio Inc. headquartered?

Annovis Bio Inc. is headquartered in Malvern, Pennsylvania.

How can I learn more about Annovis Bio Inc.?

For more information, visit the company’s website at www.AnnovisBio.com, and their social channels on LinkedIn, X, and YouTube.

Where can I find the latest news and updates about Annovis Bio Inc.?

The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.

What is the significance of Annovis Bio’s Phase 3 Alzheimer’s disease trial?

The Phase 3 trial represents a pivotal step in Annovis Bio’s efforts to develop transformative therapies for Alzheimer’s disease, with Hui Liu’s appointment aimed at enhancing the trial’s scientific and regulatory framework.